| Literature DB >> 34590550 |
Hai-Tao Yang1, Wen-Juan Xiu1, Jing-Kun Liu2, Yi Yang1, Xian-Geng Hou1, Ying-Ying Zheng3, Ting-Ting Wu1, Chen-Xin Wu1, Xiang Xie1.
Abstract
Asymptomatic hyperuricemia (AH) is an early stage of gout. Emerging evidence shows that the intestinal microbiota is related to gout. However, the relationship between AH and the intestinal microbiota is poorly understood. Therefore, the aim of the current study was to explore the possible correlation between AH and intestinal flora. We compared the intestinal microbial communities of AH (45 cases) and healthy subjects (45 cases) by 16S rRNA gene sequencing and clustering analysis on the incorporated population. Intestinal-type clustering can be divided into two groups, and significant differences in the proportion of AH are found among different bowel types. Alpha diversity indices were higher in the AH group than in the control group, and beta diversity indices also showed significant differences. A total of 19 genera were found different between the AH group and the control group. Compared with the control group, some probiotics are increased in the AH population. Two groups were ranked by importance of bacteria. We found the different bacteria partially coincided with the important bacteria, and the joint diagnosis level of the important bacteria was good.Entities:
Keywords: 16s rRNA gene; Asymptomatic hyperuricemia; diagnostic model; gut microbiota; probiotics
Mesh:
Year: 2021 PMID: 34590550 PMCID: PMC8806635 DOI: 10.1080/21655979.2021.1976897
Source DB: PubMed Journal: Bioengineered ISSN: 2165-5979 Impact factor: 3.269
Baseline characteristics of 90 patients
| Variable | Value |
|---|---|
| 60(49–66.25) | |
| 57 (63.33%) | |
| 25.56(22.65–28.67) | |
| 127 ± 15 | |
| Never | 28(31.11%) |
| Past | 30(33.33%) |
| Current | 32(35.56%) |
| Never | 65(72.22%) |
| 1–4 | 10(11.11%) |
| 5–8 | 11(12.22%) |
| >8 | 4(4.44%) |
| coronary heart disease | 55(61.11%) |
| hypertension | 44(48.89%) |
| diabetes | 13(14.44%) |
| hyperuricemia | 45(50%) |
| White blood cells, ×109/L | 6.86 ± 2.19 |
| Neutrophilicgranulocyte,% | 58.79 ± 12.89 |
| Hemoglobin, ×1012/L | 142(131–150.25) |
| Platelets, ×109/L | 216(174.75–258) |
| blood urea nitrogen,mmol/L | 5.1(4.2–5.95) |
| Creatinine,umol/L | 68.87(60–77) |
| uric acid,umol/L | 389(306–438.1) |
| Glucose, mmol/L | 4.86(4.32–5.77) |
| Total cholesterol, mmol/L | 3.77(3.08–4.54) |
| Triglyceride, mmol/L | 1.52(1.17–2.35) |
| high density lipoprotein,mmol/L | 140.54 ± 18.14 |
| total bilirubin,umol/L | 11.3(8.6–14.2) |
| γ-glutamyl transpeptadase,U/L | 25.5(18–39.25) |
Data are presented as median (interquartile range), mean±SD, or number (%).
Figure 1.A:Chao1 curves of each sample; the estimated operational taxonomic unit richness basically approached saturation in all samples.B:The number of enterotype was calculated according to CH index. C: Jensen–Shannon-based principal coordinates analysis
Figure 2.Taxonomic composition of the gut microbiome of patients. double pie chart (inner circle: phylum level, outer circle: genus level)
Clinical characteristics of patients according to enterotype
| Variable | Enterotype 1 (n = 50) | Enterotype2 (n = 40) | P value |
|---|---|---|---|
| 58.5(46.75–68.25) | 62(52.25–65) | 0.804 | |
| 33(66%) | 24(60%) | 0.356 | |
| 25.2(20.43–28.55) | 25.82(24.06–28.99) | 0.162 | |
| 128 ± 14 | 125 ± 15 | 0.306 | |
| 0.375 | |||
| Never or Past | 31(62%) | 27(67.5%) | |
| Current | 19(38%) | 13(32.5%) | |
| 0.388 | |||
| Non-heavy drinker | 35(70%) | 30(75%) | |
| Heavy drinker* | 15(30%) | 10(25%) | |
| coronary heart disease | 31(62%) | 24(60%) | 0.509 |
| hypertension | 26(52%) | 18(45%) | 0.222 |
| diabetes | 9(18%) | 4(10%) | 0.327 |
| hyperuricemia | 9(18%) | 36(90%) | <0.001 |
| White blood cells, ×109/L | 6.57 ± 1.88 | 7.03 ± 2.56 | 0.964 |
| Neutrophilicgranulocyte,% | 56.54 ± 12.62 | 60.78 ± 12.8 | 0.341 |
| Hemoglobin, ×1012/L | 142(125.5–151.25) | 140(131–146) | 0.586 |
| Platelets, ×109/L | 216(174–263.5) | 210(151.5–254.5) | 0.145 |
| blood urea nitrogen,mmol/L | 4.6(4–6.03) | 5.65(4.3–6.63) | 0.045 |
| Creatinine,umol/L | 63(54–73.13) | 71(60–78.75) | 0.019 |
| UA,umol/L | 321.5(261–393.5) | 441.35(412.25–494) | <0.001 |
| Glucose, mmol/L | 4.69(4.29–5.76) | 4.89(4.56–5.61) | 0.572 |
| Total cholesterol, mmol/L | 3.41(2.7–4.28) | 4.09(3.3–4.93) | 0.006 |
| Triglyceride, mmol/L | 1.46(1.09–2.38) | 1.63(1.09–2.51) | 0.15 |
| high density lipoprotein,mmol/L | 1.12 ± 0.28 | 1.13 ± 0.34 | 0.699 |
| total bilirubin,umol/L | 11.7(8.55–14.93) | 11(8.73–13.99) | 0.878 |
| γ-glutamyl transpeptadase,U/L | 21(16.75–43.63) | 30.5(21.18–38.33) | 0.273 |
Data are presented as median (interquartile range), mean±SD, or number (%).*Drinking status, more than 8 standard drinks/wk.
Figure 3.Taxonomic composition of the gut microbiome according to the asymptomatic hyperuricemia and control groups. double pie chart (inner circle: phylum level, outer circle: genus level). A: the asymptomatic hyperuricemia groups; B:control groups
Figure 4.Comparison of fecal microbial diversity, as estimated by the Shannon index(a), Chao1 index(b), Ace index(c) and goods_coverage index(d). A: the asymptomatic hyperuricemia groups; B:control groups
Figure 5.Differences in beta diversity indices between asymptomatic hyperuricemia and healthy groups measured with Adonis test and PCOA. The horizontal and vertical axes represent the first and second principal coordinates explaining the greatest proportion of variance to the bacterial communities (showed by percentage). A: the asymptomatic hyperuricemia groups; B:control groups; PCOA: principal coordinates analysis
Figure 6.(a) clustering tree showing significant taxonomic differences in the gut microbiota between AH (negative score) and control (positive score) groups through LEfSe analysis (LDA scores (log10) >3). (b) Cladogram indicating the phylogenetic distribution of the gut microbiota in AH and control groups through LEfSe analysis (LDA scores (log10) >3). AH: asymptomatic hyperuricemia; p: phylum; c: class; o: order; f: family; g: genus; LEfSe: linear discriminant analysis effect size; LDA: linear discriminant analysis. #:Tentative names in greenenes database
Figure 7.Important biomarkers.[A] The top 10 bacteria belong to the genus level.[B] ROCs curve with AUC for the diagnostic performance of the gut microbial model